Newsroom
Sorted by: Latest
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Artificial Intelligence UCITS ETF 18.03.2026 FTAI IE000YIQZ0H6 200,002.00 USD 4,554,329.01 22.771 ...
-
Lithium Americas Reports Full Year 2025 Results
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lithium Americas Corp. (TSX: LAC) (NYSE: LAC) (“Lithium Americas” or the “Company”) announced that it has filed its Annual Report on Form 10-K, which includes the Company’s audited consolidated financial statements for the year ended December 31, 2025, and provided an update on its Thacker Pass lithium project in Humboldt County, Nevada (“Thacker Pass” or the “Project”). Jonathan Evans, President and Chief Executive Officer of Lithium Americas said,...
-
AECOM awarded position on $151-billion U.S. MDA SHIELD contract
DALLAS--(BUSINESS WIRE)--AECOM (NYSE: ACM), the trusted global infrastructure leader, today announced it was awarded a position on the U.S. Missile Defense Agency’s Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) indefinite-delivery/indefinite-quantity contract. With a ceiling of $151 billion, the contract encompasses a broad range of work areas that allow for the rapid delivery of innovative capabilities with increased speed and agility. “This award reinforces the trust that o...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Max Buffer UCITS ETF- June 18.03.2026 MJUN LN IE000CO3P697 150,002.00 USD 3,723,338.98 24.822 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - December 18.03.2026 QDEC.LN IE000GAKWFA7 450,002.00 USD 10,105,267.50 22.456 ...
-
Signet Jewelers Reports Fourth Quarter and Full Year Fiscal 2026 Results
HAMILTON, Bermuda--(BUSINESS WIRE)--Signet Jewelers Limited ("Signet" or the "Company") (NYSE:SIG) today announced its results for the 13 and 52 weeks ended January 31, 2026 ("fourth quarter Fiscal 2026" and "full year Fiscal 2026", respectively). "FY26 delivered over a point of comp growth driven by heightened focus on our three largest brands – Kay, Zales, and Jared. Building on that momentum, FY27 will focus on accelerating core performance through sharper brand differentiation, broader cust...
-
NuScale Power and Ebara Elliott Energy Announce a Strategic Partnership to Showcase Use of Advanced Nuclear Technology to Power Petrochemical Plants
CORVALLIS, Ore.--(BUSINESS WIRE)--NuScale & Ebara Elliott Energy partner to examine the development, demonstration and field testing of an industrial scale steam compressor using NPMs...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Europe Infrastructure UCITS ETF 18.03.2026 FTEI.LN IE000TIZ5AP4 150,002.00 EUR 3,021,953.91 20.146 ...
-
NATIXIS UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name o...
-
TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in people with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer (mHSPC). The study m...